| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $323,693 | 1 | 5 |
Sells | $19,438,267 | 21 | 95 |
| Gallagher Cam | director | 1 | $323,693 | 0 | $0 | $323,693 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance | 0 | $0 | 2 | $23,310 | $-23,310 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | 0 | $0 | 2 | $58,202 | $-58,202 |
| SCHACHLE JOSEPH K | Chief Operating Officer | 0 | $0 | 4 | $74,692 | $-74,692 |
| Gagnon Robert E. | Chief Financial Officer | 0 | $0 | 3 | $113,249 | $-113,249 |
| YERXA BENJAMIN R | President | 0 | $0 | 3 | $178,550 | $-178,550 |
| Magrath George | Chief Executive Officer | 0 | $0 | 4 | $239,284 | $-239,284 |
| Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | 0 | $0 | 3 | $18.75M | $-18.75M |
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light …
Over the last 12 months, insiders at Opus Genetics, Inc. have bought $323,693 and sold $19.44M worth of Opus Genetics, Inc. stock.
On average, over the past 5 years, insiders at Opus Genetics, Inc. have bought $266,143 and sold $19.44M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Gallagher Cam (director) — $323,693.
The last purchase of 164,000 shares for transaction amount of $323,693 was made by Gallagher Cam (director) on 2025‑12‑29.
| 2026-10-23 | Sale | Magrath George | Chief Executive Officer | 9,591 0.0104% | $3.58 | $34,384 | +5.76% | |
| 2026-10-23 | Sale | YERXA BENJAMIN R | President | 33,189 0.0354% | $3.54 | $117,365 | +5.76% | |
| 2026-10-23 | Sale | Gagnon Robert E. | Chief Financial Officer | 14,000 0.015% | $3.55 | $49,650 | +5.76% | |
| 2026-10-23 | Sale | SCHACHLE JOSEPH K | Chief Operating Officer | 4,767 0.0051% | $3.56 | $16,994 | +5.76% | |
| 2026-09-30 | Sale | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | 556,000 0.6897% | $4.96 | $2.76M | -16.74% | |
| 2026-07-23 | Sale | Magrath George | Chief Executive Officer | 9,475 0.0116% | $2.95 | $27,926 | +38.36% | |
| 2026-07-23 | Sale | YERXA BENJAMIN R | President | 7,429 0.0092% | $2.97 | $22,064 | +38.36% | |
| 2026-07-23 | Sale | Gagnon Robert E. | Chief Financial Officer | 7,783 0.0095% | $2.95 | $22,942 | +38.36% | |
| 2026-07-23 | Sale | SCHACHLE JOSEPH K | Chief Operating Officer | 4,644 0.0057% | $2.94 | $13,653 | +38.36% | |
| 2026-05-18 | Sale | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | 1.7M 2.0462% | $4.35 | $7.39M | -8.78% | |
| 2026-04-23 | Sale | Magrath George | Chief Executive Officer | 9,511 0.0134% | $5.22 | $49,647 | -21.69% | |
| 2026-04-23 | Sale | YERXA BENJAMIN R | President | 7,470 0.0106% | $5.24 | $39,121 | -21.69% | |
| 2026-04-23 | Sale | Gagnon Robert E. | Chief Financial Officer | 7,842 0.011% | $5.18 | $40,658 | -21.69% | |
| 2026-04-23 | Sale | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | 7,542 0.0106% | $5.19 | $39,156 | -21.69% | |
| 2026-04-23 | Sale | SCHACHLE JOSEPH K | Chief Operating Officer | 4,697 0.0066% | $5.22 | $24,519 | -21.69% | |
| 2026-04-23 | Sale | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | 1,641 0.0023% | $5.20 | $8,540 | -21.69% | |
| 2026-03-16 | Sale | Magrath George | Chief Executive Officer | 24,438 0.0356% | $5.21 | $127,327 | -19.08% | |
| 2026-03-16 | Sale | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | 3,719 0.0053% | $5.12 | $19,046 | -19.08% | |
| 2026-03-16 | Sale | SCHACHLE JOSEPH K | Chief Operating Officer | 3,719 0.0055% | $5.25 | $19,525 | -19.08% | |
| 2026-03-16 | Sale | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | 2,816 0.0041% | $5.25 | $14,770 | -19.08% |
| Magrath George | Chief Executive Officer | 2038894 2.4507% | $8.01M | 3 | 4 | +10.7% |
| Gallagher Cam | director | 1891430 2.2735% | $7.43M | 1 | 0 | |
| YERXA BENJAMIN R | President | 670917 0.8064% | $2.64M | 1 | 3 | +12.79% |
$31,123,523 | 108 | 6.46% | $387.86M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$10,399,379 | 13 | 13.60% | $302.03M |
| Increased Positions | 34 | +80.95% | 9M | +47.2% |
| Decreased Positions | 13 | -30.95% | 286,648 | -1.51% |
| New Positions | 15 | New | 5M | New |
| Sold Out Positions | 5 | Sold Out | 61,846 | Sold Out |
| Total Postitions | 63 | +50% | 28M | +45.69% |